[go: up one dir, main page]

MX344772B - Analogos de estilbeno y metodos para tratar cancer. - Google Patents

Analogos de estilbeno y metodos para tratar cancer.

Info

Publication number
MX344772B
MX344772B MX2013008750A MX2013008750A MX344772B MX 344772 B MX344772 B MX 344772B MX 2013008750 A MX2013008750 A MX 2013008750A MX 2013008750 A MX2013008750 A MX 2013008750A MX 344772 B MX344772 B MX 344772B
Authority
MX
Mexico
Prior art keywords
methods
stilbene
treating cancer
stilbene analogs
analogs
Prior art date
Application number
MX2013008750A
Other languages
English (en)
Other versions
MX2013008750A (es
Inventor
S Watt David
Liu Chunming
Zhang Wen
M Sviripa Vitaliy
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Publication of MX2013008750A publication Critical patent/MX2013008750A/es
Publication of MX344772B publication Critical patent/MX344772B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/45—Monoamines
    • C07C211/48—N-alkylated amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/56—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/57—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
    • C07C211/60—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton containing a ring other than a six-membered aromatic ring forming part of at least one of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
    • C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/148—Stilbene dyes containing the moiety -C6H5-CH=CH-C6H5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen análogos de estilbeno y composiciones farmacéuticas que son útiles para el tratamiento de varios cánceres, incluyendo sin limitación, cáncer colorectal (CRC) y cáncer de mama. Los análogos de estilbeno halogenados incluyen grupos de heteroarilo nitrógeno y/o grupos amino en el anillo estilbeno.
MX2013008750A 2011-01-28 2012-01-27 Analogos de estilbeno y metodos para tratar cancer. MX344772B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161437341P 2011-01-28 2011-01-28
US201161439118P 2011-02-03 2011-02-03
PCT/US2012/022938 WO2012103457A2 (en) 2011-01-28 2012-01-27 Stilbene analogs and methods of treating cancer

Publications (2)

Publication Number Publication Date
MX2013008750A MX2013008750A (es) 2014-04-25
MX344772B true MX344772B (es) 2017-01-06

Family

ID=46577838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008750A MX344772B (es) 2011-01-28 2012-01-27 Analogos de estilbeno y metodos para tratar cancer.

Country Status (7)

Country Link
US (2) US8664276B2 (es)
EP (1) EP2673250B1 (es)
JP (1) JP2014512337A (es)
CN (3) CN105622431A (es)
CA (1) CA2826034A1 (es)
MX (1) MX344772B (es)
WO (1) WO2012103457A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841350B2 (en) 2011-05-11 2014-09-23 ChromaDex Inc. Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
CN105142622A (zh) * 2012-10-15 2015-12-09 变色蜥制药公司 硫雌酚用于治疗癌症
US9895324B2 (en) 2014-03-26 2018-02-20 University Of Kentucky Research Foundation Halogenated diarylacetylenes and methods of treating cancer
CN105200077B (zh) * 2015-10-09 2018-08-24 中南大学 Btrc基因的过表达试剂及其制备和应用方法
AU2016364855B2 (en) * 2015-12-03 2019-08-29 Les Laboratoires Servier MAT2A inhibitors for treating MTAP null cancer
CN105997992B (zh) * 2016-06-02 2019-10-01 北京北科德源生物医药科技有限公司 化合物dy1在制备抗大肠癌药物中的应用
MX2019002303A (es) * 2016-08-31 2019-07-15 Agios Pharmaceuticals Inc Inhibidores de procesos metabolicos celulares.
AU2018210393A1 (en) 2017-01-20 2019-07-25 The Regents Of The University Of California Inhibitors of the N-terminal domain of the androgen receptor
US11389460B2 (en) 2017-09-15 2022-07-19 City Of Hope Methods and compositions for treating endometrial cancer
US11459293B2 (en) * 2017-10-27 2022-10-04 Immunebridge Inc. Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene
US11376256B2 (en) * 2018-07-19 2022-07-05 Agency For Science, Technology And Research Method of treating a methionine-dependent cancer
MA54608B1 (fr) 2018-12-27 2023-02-28 Servier Lab Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
CN111153817B (zh) * 2020-01-20 2021-02-02 四川大学 苯氧基-n-苯基苯胺衍生物及其应用
JP2024116429A (ja) * 2021-07-06 2024-08-28 国立研究開発法人産業技術総合研究所 組織の老化を予防または治療するための組成物
US20250090533A1 (en) * 2021-11-12 2025-03-20 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a taxane
DE102022129894A1 (de) * 2022-11-11 2024-05-16 Technische Universität Dresden, Körperschaft des öffentlichen Rechts 4-Hydroxybicyclo[3.3.1]non-3-en-2,9-dion-Derivate und deren Verwendung

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847908A (en) * 1973-03-05 1974-11-12 Squibb & Sons Inc 6-styrylpyrazolo(3,4-d)pyrimidinones and pyrimidines
US4683087A (en) 1983-08-26 1987-07-28 The Ohio State University Research Foundation Anti-cancer agents and processes for their preparation
JPH0285828A (ja) * 1988-09-22 1990-03-27 Sekisui Chem Co Ltd 有機非線形光学材料
US5223503A (en) * 1991-04-29 1993-06-29 Eli Lilly And Company 6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents
JP2799101B2 (ja) * 1992-03-04 1998-09-17 シャープ株式会社 有機非線形光学材料
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
TW325458B (en) * 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
DE69931766T2 (de) 1998-04-03 2007-05-31 Ajinomoto Co., Inc. Antitumorale mittel
AU7596100A (en) 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
GB0001565D0 (en) * 2000-01-24 2000-03-15 Isis Innovation Dihydrofolate reductase inhibitors
US6552085B2 (en) 2000-08-16 2003-04-22 Insmed Incorporated Compositions containing hypoglycemically active stilbenoids
IL155509A0 (en) 2000-10-27 2003-11-23 Aventis Pharma Sa A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
US20030077616A1 (en) * 2001-04-19 2003-04-24 Ciphergen Biosystems, Inc. Biomolecule characterization using mass spectrometry and affinity tags
WO2003018070A1 (en) * 2001-08-27 2003-03-06 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
US6919324B2 (en) 2001-10-26 2005-07-19 Oxigene, Inc. Functionalized stilbene derivatives as improved vascular targeting agents
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
CA2483496A1 (en) * 2002-04-26 2003-11-06 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
DK1511718T3 (da) * 2002-05-29 2009-06-22 Hoffmann La Roche N-acylaminobenzenderivater som selektive monoaminoxidase B-inhibitorer
CA2496624A1 (en) * 2002-09-17 2004-04-01 Actelion Pharmaceuticals Ltd 1-pyridin-4-yl-urea derivatives
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
US7531578B2 (en) 2003-09-18 2009-05-12 City Of Hope Compounds and methods for treating breast cancer and other diseases
JP2005350363A (ja) * 2004-06-08 2005-12-22 Kyorin Pharmaceut Co Ltd ヘムオキシゲナーゼの誘導または誘導促進剤としての４−トリフルオロメチルピリミジン誘導体
CN101106992A (zh) * 2005-01-18 2008-01-16 伊姆索公司 新颖的喹啉鎓盐和衍生物
JP2008540560A (ja) 2005-05-12 2008-11-20 アリゾナ・ボード・オブ・リージェンツ・ア・ボディ・コーポレート・オブ・ザ・ステート・オブ・アリゾナ・アクティング・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステート・ユニバーシティ スチルベン誘導体並びにがん細胞増殖及び微生物増殖の阻害方法
WO2007054776A2 (en) 2005-11-10 2007-05-18 Orchid Research Laboratories Limited Stilbene like compounds as novel hdac inhibitors
US8980954B2 (en) 2006-04-25 2015-03-17 Stc.Unm Substituted cis- and trans-stilbenes as therapeutic agents
KR101435228B1 (ko) 2006-07-14 2014-08-28 디에스엠 아이피 어셋츠 비.브이. 조성물, 및 염증성 질환의 치료, 병용-치료 또는 예방을 위한 이의 용도
TW200819409A (en) * 2006-10-19 2008-05-01 Univ Taipei Medical Z-stilbenes derivatives and the pharmaceutical composition thereof
WO2008070872A1 (en) 2006-12-07 2008-06-12 Rutgers, The State University Of New Jersey Prevention and treatment of colon cancer
US7781580B2 (en) 2007-04-23 2010-08-24 Virginia Commonwealth University Stilbene derivatives as new cancer therapeutic agents
TW201020238A (en) * 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US20100119499A1 (en) 2009-09-17 2010-05-13 Kneller Bruce W Stilbene-based compositions and methods of use therefor

Also Published As

Publication number Publication date
CN103764604B (zh) 2017-02-08
JP2014512337A (ja) 2014-05-22
CN110015962B (zh) 2022-03-15
CA2826034A1 (en) 2012-08-02
EP2673250A2 (en) 2013-12-18
US9132102B2 (en) 2015-09-15
US8664276B2 (en) 2014-03-04
WO2012103457A2 (en) 2012-08-02
EP2673250B1 (en) 2016-11-23
WO2012103457A3 (en) 2012-10-11
MX2013008750A (es) 2014-04-25
CN110015962A (zh) 2019-07-16
EP2673250A4 (en) 2014-06-25
CN105622431A (zh) 2016-06-01
CN103764604A (zh) 2014-04-30
US20120196874A1 (en) 2012-08-02
US20140249161A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
MX344772B (es) Analogos de estilbeno y metodos para tratar cancer.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
PH12016502354A1 (en) Pharmaceutical composition
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
PH12012502194A1 (en) Indoles
MY177344A (en) Compounds and their methods of use
WO2014018563A3 (en) Methods for the treatment of cancer
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
MX373324B (es) Compuestos piridínicos de pladienolida y métodos de uso.
MX2018010993A (es) Derivados de icariina e icaritina.
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer
PH12015501088A1 (en) Dimeric compounds
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
EP2670763A1 (en) Certain chemical entities, compositions, and methods
MX2016009663A (es) Derivados de icariina.
MX2018001576A (es) Piridinas y su uso en el tratamiento del cancer.
PH12017500853B1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
EA201990624A1 (ru) Иммуногенные композиции tert и способы лечения с их использованием

Legal Events

Date Code Title Description
FG Grant or registration